Plasma      ( nmole/min/ml)

Liver  (nmole/min/gm tissue)

  Kideny ( nmole/min/gm tissue)

Brain (nmole/min/gm tissue)

 

XO

GST

XO

GST

XO

GST

XO

GST

Control group

135.4 ± 8.56

14.33 ±  1.52

44.10 ±  2.65

25.12 ±  1.87

58.84 ±  4.23

36.41 ±  3.78

111.02 ±  7.49

9.11 ±  1.02

Cd exposed group

296.3 ±  10.22***

18.96 ±  1.10***

87.33 ±  6.02***

51.05 ±  2.64***

64.20 ±  3.63*

42.16 ±  2.81***

144.89 ±  9.48***

13.40 ±  1.47***

Ceftriaxone plus sulbactam with VRP1034 group

168.7 ±  14.31***

13.74 ±  0.55***

71.82 ±  4.49***

37.0 ±  2.09***

56.22 ± 1.77***

40.33 ±   1.59ns

139.45 ±  8.80ns

10.00 ±  1.12***
All data are Mean ± SD of each group. The XO and GST levels were expressed in the plasma (μmole/min/ml) whereas in the tissues (μmole/gm tissue). Newman keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant) **p<0.01(significant); *p<0.05 (significant) Nsp>0.05 (non significant).
Table 4: Effect of ceftriaxone plus sulbactam with VRP1034 on xanthine oxidase (XO) and gluathione s transferase (GST) in cadmium exposed group after 21 days treatment.